Autoren
Dr. John O'Brien
Life/Health Chief Medical Officer, London
Dr. John O'Brien is the Chief Medical Officer (CMO) for Gen Re Life/Health Research and Development, based in the UK. Before joining Gen Re as CMO, he worked as consultant for Gen Re in Cape Town while running a pulmonology practice and clinical trial centre. Dr. O'Brien is a past president of the South African Thoracic Society and served on the editorial committees for the South African Thoracic Society guidelines for asthma and COPD. He has been a clinical investigator in more than 70 clinical trials in asthma and COPD.
-
Les tests génétiques à la loupe
Von Dr. John O'Brien Nov 18, 2019Français
Les tests génétiques se démocratisent et de nouveaux liens entre gènes et maladies sont régulièrement identifiés. Toutefois, en raison des nombreuses contraintes qui pèsent sur l’utilisation des tests génétiques prédictifs dans le domaine de l’assurance,...
Erfahren Sie mehr -
When Is a Heart Attack a Heart Attack?
Von Dr. John O'Brien Nov 05, 2019English
Right up until the 1960s no specific treatment for heart attack existed; patients were simply advised to go home and rest in bed. Today, although our understanding and treatment of what’s technically called myocardial infarction (MI) has come a long way,...
Erfahren Sie mehr -
Chronic Myeloid Leukaemia - From Fatal to Chronic Disease
Von Dr. John O'Brien Oct 16, 2019English
Major advances in the treatment of chronic myeloid leukaemia (CML) have produced a welcome improvement in its prognosis. CML used to be a universally fatal condition; now, for some patients, it can be considered a chronic illness with little impact on...
Erfahren Sie mehr -
Underwriting Focus 2019, No. 1
Ausgabe: Oct 14, 2019Français
Avancées médicales dans la tarification / Cardiologie / Leucémie myéloïde chronique / Orthopédie / Les innovations dans la tarification des assurances-vie
Kunden-Login erforderlich Erfahren Sie mehr
Meistgelesen
Themen
Capital Management
Life/Health
Property/Casualty
Autoren
Lernen Sie unsere Experten kennen
